05:54 PM EDT, 10/22/2024 (MT Newswires) -- Pfizer ( PFE ) said Tuesday the US Food and Drug Administration approved its Abrysvo vaccine to prevent lower respiratory tract disease caused by respiratory syncytial virus in individuals aged 18 and above.

Abrysvo's indication previously included adults aged 60 years and above, the drugmaker said.

Price: 28.90, Change: +0.06, Percent Change: +0.21